Yingxiao Shi

Yingxiao Shi

Auto-generated profile, based on publicly available information

Yingxiao Shi

Division of Population Sciences, Dana-Farber Cancer Institute; Boston, MA, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
TTTetsuo Tani
Tetsuo Tani
HMHaritha Mathsyaraja
Haritha Mathsyaraja
Marco CampisiMarco Campisi
Marco Campisi
ZLZe-Hua Li
Ze-Hua Li
KHKoji Haratani
Koji Haratani
DBDavid A Barbie
David A Barbie
A substantial fraction of cancers evade immune detection by silencing Stimulator of Interferon Genes (STING)-Interferon (IFN) signaling. Therapeutic reactivation of this program via STING agonists, epigenetic, or DNA-damaging therapies can restore antitumor immunity in multiple preclinical models. Here we show that adaptive induction of three prime exonuclease 1 (TREX1) restrains STING-dependent nucleic acid sensing in cancer cells via its catalytic function in degrading cytosolic DNA. Cancer cell TREX1 expression is coordinately induced with STING by autocrine IFN and downstream STAT1, preventing signal amplification. TREX1 inactivation in cancer cells thus unleashes STING–IFN signaling, recruiting T and natural killer (NK) cells, sensitizing to NK cell–derived IFNγ, and cooperating with programmed cell death protein 1 blockade in multiple mouse tumor models to enhance immunogenicity. Targeting TREX1 may represent a complementary strategy to induce cytosolic DNA and amplify cancer cell STING–IFN signaling as a means to sensitize tumors to immune checkpoint blockade (ICB) and/or cell therapies. Significance: STING–IFN signaling in cancer cells promotes tumor cell immunogenicity. Inactivation of the DNA exonuclease TREX1, which is adaptively upregulated to limit pathway activation in cancer cells, recruits immune effector cells and primes NK cell–mediated killing. Targeting TREX1 has substantial therapeutic potential to amplify cancer cell immunogenicity and overcome ICB resistance. This article is featured in Selected Articles from This Issue, p. 695

24 June 2025 in bioRxiv
Verified
Preprint
Open access
TVTuulia Vallius
Tuulia Vallius
YSYingxiao Shi
Yingxiao Shi
ENEdward Novikov
Edward Novikov
SPShishir M Pant
Shishir M Pant
RPRoxanne Pelletier
Roxanne Pelletier
PSPeter K Sorger
Peter K Sorger
Localized cutaneous melanoma can be cured by excision but success critically depends on early detection and risk assessment of primary lesions. However, their initiation, progression, and immunology remain poorly understood, partly due to high intra- and inter-tumor heterogeneity. We studied this heterogeneity using spatial profiling in over 300 histological domains, each representing a single progression stage, and found that 200-600 cell neighborhoods from a single melanoma can be as different in RNA and protein expression as neighborhoods from different tumors. These differences are not stochastic, however, and disease progression can be mapped at the neighborhood level onto a cell state landscape defined by the activity of the melanocyte master regulator MITF and genes associated with a dedifferentiated neural crest phenotype. Position in this landscape is influenced by proximity to immune cells, perivascular environments, and other tissue features, but no single association is absolute, giving rise to complex spatial patterns.

9 September 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MVMadhvi J. Venkatesh
Madhvi J. Venkatesh
AEAlexandra R. Elchert
Alexandra R. Elchert
BFBolutife Fakoya
Bolutife Fakoya
FFFrancisco Fernandez
Francisco Fernandez
AKAndrew C. Kwong
Andrew C. Kwong
JLJoseph J. Loparo
Joseph J. Loparo

15 December 2025 in bioRxiv
Verified
Preprint
Open access
YSYingxiao Shi
Yingxiao Shi
ZMZoltan Maliga
Zoltan Maliga
TVTuulia Vallius
Tuulia Vallius
SPShishir M Pant
Shishir M Pant
RPRoxanne Pelletier
Roxanne Pelletier
PSPeter Karl Sorger
Peter Karl Sorger
Tumor dormancy is thought to enable cancer recurrence, but the settings and mechanisms of dormancy in patients are poorly characterized. Both immunogenic tumor mass dormancy, involving continued tumor cell proliferation and balanced immune-mediated cell death, and cell-level quiescence have been observed in preclinical models. Here, we demonstrate the existence of mass dormancy rather than quiescence in long-term stable residual lesions in melanoma patients treated with immune checkpoint inhibitors (ICI). In a large stable lesion subjected to detailed spatial profiling, the proportion of proliferating tumor cells is similar to that in site-matched tumors from patients progressing after ICI. Residual stable lesions from other patients, judged to contain only scar tissue upon clinical pathology review, also contained nests of dividing tumor cells surrounded by active immune cells. These findings demonstrate the presence of viable tumor cells and mass dormancy in persistent stable lesions, a finding with implications for disease monitoring and management.

6 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
YSYingxiao Shi
Yingxiao Shi
PSPriyanka Sharma
Priyanka Sharma
JLJia-Ren Lin
Jia-Ren Lin
ADAikaterini Dedeilia
Aikaterini Dedeilia
TVTuulia Vallius
Tuulia Vallius
GBGenevieve Boland
Genevieve Boland
Mucosal melanoma is a rare, lethal melanoma subtype with distinct genetics and limited benefit from immunotherapy. To define features associated with mucosal melanoma clinical outcomes, we assembled a large, multimodally profiled cohort spanning primary and metastatic disease. Compared with cutaneous melanoma, primary mucosal melanoma showed greater genomic heterogeneity, ploidy and aneuploidy, and a more dedifferentiated, proliferative transcriptional state. Analysis of genomic sequencing of 339 patients with mucosal melanoma identified four mutually exclusive genomic subtypes: CDK4/MDM2/CCND1, SF3B1-mutated, TP53/ATRX, and mucosal melanoma Triple WT, associated with distinct anatomic sites but similar outcomes. In the tumor microenvironment, we observed reduced T cell infiltration and increased CD163 + tumor-associated macrophages in mucosal melanoma relative to cutaneous melanoma. In matched longitudinal samples, CD163 + tumor-associated macrophages increased with disease progression and immunotherapy resistance. CD163 + tumor-associated macrophages engaged non-regulatory T cells through GAL9–TIM-3 interactions, nominating TIM-3 blockade as a therapeutic strategy for mucosal melanoma. These findings define the distinct aggressive biology of mucosal melanoma and highlight potential therapeutic targets and mechanisms of immune resistance.

1 May 2024
Verified
Other
Open access
TTTetsuo Tani
Tetsuo Tani
HMHaritha Mathsyaraja
Haritha Mathsyaraja
Marco CampisiMarco Campisi
Marco Campisi
ZLZe-Hua Li
Ze-Hua Li
KHKoji Haratani
Koji Haratani
DBDavid A Barbie
David A Barbie
Supplementary figureS3 shows the figures related to Figure 3.